

## Nepal

### Support for Injection Safety Devices

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b>	Nepal						
<b>2. Grant number(s):</b>	17-NPL-32a-X, 18-NPL-32a-X, 19-NPL-32a-X, 20-NPL-32a-X, 21-NPL-32a-X						
<b>3. Date of Decision Letter:</b>	30 September 2019						
<b>4. Date of the Partnership Framework Agreement:</b>	22 August 2014						
<b>5. Programme title:</b>	Injection Safety Devices <sup>1</sup>						
<b>6. Programme Duration:<sup>2</sup></b>	2017-2021						
<b>7. Programme Budget (indicative):<sup>3</sup></b>	<b>(subject to the terms of the Partnership Framework Agreement, if applicable)</b>						
	<b>2017-2019</b>	<b>2020</b>	<b>2021</b>	<b>2022</b>	<b>2023</b>	<b>2024</b>	<b>Total<sup>2</sup></b>
Programme Budget (US\$)	761,776	212,500	177,500	-	-	-	1,151,776
<b>8. Indicative Annual Amounts:<sup>4</sup></b>	<b>(subject to the terms of the Partnership Framework Agreement, if applicable)</b>						
<b>Total injection safety devices to be purchased with Gavi funds in each year</b>	<b>2017-2019</b>	<b>2020</b>	<b>2021</b>				
Number of AD syringes		4,505,800	-				
Number of re-constitution syringes		72,200	-				
Number of safety boxes		50,400	-				
<b>Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</b>	<b>761,776</b>	<b>212,500</b>	<b>-</b>				
<b>Injection safety devices to be purchased with Gavi funds in each year, by type of support</b>							
<i>Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u></i>							
<b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 1 dose(s) per vial, LIQUID - Routine</b>		<b>2020</b>	<b>2021</b>				
Number of AD syringes		1,298,300	-				
Number of re-constitution syringes		-	-				
Number of safety boxes		14,300	-				
Annual Amounts for injection safety devices for vaccine (US\$)		63,000	-				

<sup>1</sup> This does not include vaccines.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>4</sup> This is the amount that Gavi has approved.

<b>New Vaccine Support (NVS), Measles Rubella, 10 dose(s) per vial, LYOPHILISED - SD Routine - Strat 1</b>	<b>2020</b>	<b>2021</b>
Number of AD syringes	432,100	-
Number of re-constitution syringes	72,200	-
Number of safety boxes	5,550	-
Annual Amounts for injection safety devices for vaccine (US\$)	23,500	-
<b>New Vaccine Support (NVS), PCV10, 4 dose(s) per vial, LIQUID - Routine</b>	<b>2020</b>	<b>2021</b>
Number of AD syringes	1,443,900	-
Number of re-constitution syringes	-	-
Number of safety boxes	15,900	-
Annual Amounts for injection safety devices for vaccine (US\$)	65,500	-
<b>New Vaccine Support (NVS), Penta, 10 dose(s) per vial, LIQUID - Routine</b>	<b>2020</b>	<b>2021</b>
Number of AD syringes	1,331,500	-
Number of re-constitution syringes	-	-
Number of safety boxes	14,650	-
Annual Amounts for injection safety devices for vaccine (US\$)	60,500	-
<b>9. Procurement agency:</b>	UNICEF. The Country shall release its co-financing payments each year to UNICEF.	
<b>10. Self-procurement:</b>	Not applicable	
<b>11. Co-financing obligations:</b>	Co-financing requirements are listed in the relevant vaccine Decision Letter.	

Signed by,

**On behalf of Gavi**



Thabani Maphosa

Managing Director, Country Programmes

30 September 2019